Skip to main content

Table 1 Sample Characteristics

From: Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials

  Online survey participants
(n = 258)
In-depth interview participants
(n = 14)
  n (%)   n (%)
Region Europe 158 (61%) Spain 6 (43%)
North America 61 (24%) U.S. 8 (57%)
East Asia and the Pacific 16 (6%)   
Africa 13 (5%)   
Latin America 10 (4%)   
Clinical role Physician 156 (60%) Physician 10 (72%)
Nurse/Study Nurse/PA 64 (25%) Nurse 2 (14%)
Research Staff 29 (11%) Administrator 2 (14%)
Pharmacist 9 (4%)   
Prior LA ART trial involvement 1–2 clinical trials 134 (52%) ATLAS/ATLAS-2 M 8 (57%)
3 or more clinical trials 124 (48%) FLAIR 6 (43%)